Form 4: Jazz Pharmaceuticals SVP, Chief Accounting Officer Patricia Carr Reports Stock Sales

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, reports the sale of ordinary shares to cover tax obligations and other transactions.

Summary

• Patricia Carr, the SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, filed a Form 4 detailing changes in beneficial ownership.
• On March 7, 2025, she disposed of 1,333 ordinary shares at a price of $138.23.
• On March 10, 2025, she sold 1,140 ordinary shares at $137.81.
• Following these transactions, Carr directly owns 7,012 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as the sales are related to tax obligations.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares involved.

Key Dates